Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: A pooled analysis of controlled studies
| Autor: | Aditya Lele, Maureen T. Kelly, Robert S. Rosenson, Michael H. Davidson, Peter B. Jones, Kamlesh M. Thakker, Eli M. Roth, Carolyn M. Setze |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Time Factors Apolipoprotein B Endocrinology Diabetes and Metabolism Coronary Disease Pharmacology Gastroenterology law.invention chemistry.chemical_compound Fenofibrate Randomized controlled trial Risk Factors law Medicine Rosuvastatin Calcium Hypolipidemic Agents Sulfonamides Nutrition and Dietetics biology Middle Aged Treatment Outcome Drug Therapy Combination Female Cardiology and Cardiovascular Medicine medicine.drug Adult medicine.medical_specialty Combination therapy Internal medicine Post-hoc analysis Internal Medicine Humans Rosuvastatin Triglycerides Aged Apolipoproteins B Dyslipidemias business.industry Cholesterol Cholesterol HDL nutritional and metabolic diseases Cholesterol LDL medicine.disease Fluorobenzenes Pyrimidines chemistry biology.protein business Dyslipidemia |
| Zdroj: | Journal of Clinical Lipidology. 6:534-544 |
| ISSN: | 1933-2874 |
| DOI: | 10.1016/j.jacl.2012.02.002 |
| Popis: | Goal/desirable lipid levels are underachieved in patients with mixed dyslipidemia. These patients may have substantial residual risk of cardiovascular disease even while receiving optimal LDL-C-lowering therapy and may require additional therapy to improve multiple lipid/lipoprotein levels.To evaluate attainment of goal/desirable levels of lipids/lipoproteins after 12-week treatment with combination rosuvastatin + fenofibric acid versus rosuvastatin monotherapy.This was a post hoc analysis of patients with mixed dyslipidemia who enrolled in one of two randomized controlled trials, and were treated (N = 2066) with rosuvastatin (5, 10, or 20 mg), fenofibric acid 135 mg, or rosuvastatin + fenofibric acid for 12 weeks. Data were pooled across doses of rosuvastatin as monotherapy and combination therapy.Compared with rosuvastatin monotherapy, combination therapy had comparable effects in achieving risk-stratified LDL-C goals; however, measures of total atherogenic burden were improved because significantly greater percentages of patients attained non-HDL-C goal in high- (62.9% vs 50.4%, P = .006) and moderate-risk groups (87.6% vs 80.4%, P = .016) and apolipoprotein B (ApoB)90 mg/dL in high-risk group (59.8% vs 43.8%, P.001). In the overall population, more patients treated with the combination therapy achieved desirable levels of HDL-C40/50 mg/dL in men/women (P.001), triglycerides150 mg/dL (P.001), and ApoB90 mg/dL (P.001), compared with rosuvastatin monotherapy. Furthermore, combination therapy resulted in significantly greater percentages of patients achieving simultaneous specified levels of LDL-C + non-HDL-C (P .015); LDL-C + HDL-C + TG (P.001); and LDL-C + HDL-C + triglycerides + non-HDL-C + ApoB (P.001), compared with rosuvastatin monotherapy.Rosuvastatin + fenofibric acid may be more efficacious than rosuvastatin alone in patients with mixed dyslipidemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect